ALKS Q4 2024 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$430M+13.9% YoY

Gross Profit

$368M85.6% margin

Operating Income

$163M37.8% margin

Net Income

$147M34.1% margin

EPS (Diluted)

$0.88

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

$190M

Free Cash Flow

$181M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$591M

Stockholders' Equity

$1.5B

Cash & Equivalents

$291M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$430M	$377M	+13.9%
Gross Profit	$368M	$307M	+19.7%
Operating Income	$163M	$179M	-8.9%
Net Income	$147M	$113M	+29.9%

Revenue Segments

Product

$308M50%

Vivitrol

$134M22%

Aristada And Aristada Initio

$97M16%

L Y B A L V I

$77M13%